Oncolytic virotherapy: potentially a game-changing tumor treatment
A two-center phase I trial published in the New England Journal of Medicine shows safety and feasibility of locally administered oncolytic herpes simplex virus-1 virus plus 5 Gy radiation for progressive pediatric high-grade gliomas. Patients seemed to have an unusually good clinical course and show...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Article (Journal) |
| Lingua: | inglese |
| Pubblicazione: |
14 June 2021
|
| In: |
Cancer cell
Year: 2021, Volume: 39, Fascicolo: 6, Pages: 753-755 |
| ISSN: | 1878-3686 |
| DOI: | 10.1016/j.ccell.2021.05.014 |
| Accesso online: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ccell.2021.05.014 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1535610821002804 
|
| Note sull'autore: | Tobias Kessler and Wolfgang Wick |
| Riassunto: | A two-center phase I trial published in the New England Journal of Medicine shows safety and feasibility of locally administered oncolytic herpes simplex virus-1 virus plus 5 Gy radiation for progressive pediatric high-grade gliomas. Patients seemed to have an unusually good clinical course and showed immune activation in post-treatment tissues. |
|---|---|
| Descrizione del documento: | Gesehen am 29.09.2021 |
| Descrizione fisica: | Online Resource |
| ISSN: | 1878-3686 |
| DOI: | 10.1016/j.ccell.2021.05.014 |